Johnson & Johnson Reports Strong Q1 Earnings Despite Stelara Biosimilar Headwinds
Johnson & Johnson reported a first-quarter sales increase of 6.4% operationally, driven by growth in oncology and immunology products, despite a 540-basis-point headwind from Stelara biosimilar competition. The company raised its full-year sales guidance and announced a 3.1% dividend increase.
Tickers: $JNJ
Topics: Dividend Increase Earnings Guidance Update R&D Investment Sales Growth